HomeWashington Letter2019 ▶ UNION Symposium Showcases TB Vaccine Progress and Action Needed
UNION Symposium Showcases TB Vaccine Progress and Action Needed

Dr. David Lewinsohn

Following up on the exciting announcement of the successful trial results for the M72/AS01E TB vaccine candidate developed by GlaxoSmithKline (GSK), the UNION’s symposium, The Way Forward for TB Vaccines, provided an overview of the full TB vaccine pipeline and explored ways to accelerate progress towards new vaccines for all populations and maximize implementation impact. GSK Director of Clinical Research and Development Olivier Van Der Meeran, MD, reported that the phase II trial of 3,573 adults with TB infection in Kenya, South Africa and Zambia found that the M72/AS01E vaccine contributed to preventing active TB in 50 percent of those that received it. ATS International Health Committee chair David Lewinsohn, MD, discussed novel concepts in preclinical and early clinical TB vaccine development. Dr. Lewinsohn outlined the key areas of need to be addressed, which include development of vaccines for specific populations, including people living with HIV and children and correlates of protection.

Last Reviewed: November 2019